Drug
Tezacaftor clinical trials
Also written VX-661.
- studies test it
- 44
- open now
- 4
- in phase 3
- 26
- first study started
- 2012
Keep track of what changes. Save the tezacaftor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
44 studies that test it; most in 2016 (6)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 5 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 10
- Phase 3
- 26
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 40 · Other 4
Vertex Pharmaceuticals Incorporated (40) · Royal College of Surgeons, Ireland (1) · Nottingham University Hospitals NHS Trust (1) · Istituto Giannina Gaslini (1) · Arkansas Children's Hospital Research Institute (1)
Often tested with
Tested in the same studies.
Ivacaftor (44) · Elexacaftor (23) · Olacaftor (2) · VX-828 (1) · Vanzacaftor (1) · VX-659 (1) · VX-152 (1) · Ciprofloxacin (1)
Studies
Open first, then newest update. How each study uses tezacaftor is read from its arms, and is right about nine times in ten.
Testing it · 44
- Evaluation of VX-581 in Healthy Participants and in Participants With Cystic FibrosisRecruitingPhase 1Vertex Pharmaceuticals IncorporatedNCT07283770Written as TEZ
- Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic FibrosisRecruitingPhase 4Istituto Giannina GasliniNCT07809867Written as Elexacaftor, Tezacaftor, Ivacaftor
- Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsRecruitingPhase 1Vertex Pharmaceuticals IncorporatedNCT07437105Written as Tezacaftor
- Ensuring Access to Optimal Therapy in CF: The ENACT StudyRecruitingPhase 4Arkansas Children's Hospital Research InstituteNCT07148739Written as Elexacaftor / Ivacaftor / Tezacaftor
- Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgeCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05882357Written as ELX/TEZ/IVA
- Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delActive, not recruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT05331183Written as ELX/TEZ/IVA
- Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)Active, not recruitingPhase 4Royal College of Surgeons, IrelandNCT04602468Written as Elexacaftor/Tezacaftor/Ivacaftor
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic FibrosisCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT06154447Written as Tezacaftor
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and OlderActive, not recruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT06460506Written as ELX/TEZ/IVA
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and OlderCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05153317Written as ELX/TEZ/IVA
- A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03525574Written as ELX/TEZ/IVA
- Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label ExpansionCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT02070744Written as VX-661
- A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04969224Written as ELX/TEZ/IVA
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and OlderCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04183790Written as ELX/TEZ/IVA
- Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05274269Written as ELX/TEZ/IVA
- A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF GenotypesCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04545515Written as ELX/TEZ/IVA
- A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03537651Written as TEZ/IVA
- Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04058366Written as ELX/TEZ/IVA
- A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT02565914Written as TEZ/IVA
- A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04599465Written as ELX/TEZ/IVA
See all 44 studies that test tezacaftor →
Given in every arm · 2 — tezacaftor is usual care beside what is tested
- A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic FibrosisCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT03912233Written as TEZ
- A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic FibrosisCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT03029455Written as Tezacaftor
As the comparator · 5 — what is tested is compared with tezacaftor
- A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05033080Written as ELX/TEZ/IVA
- A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05076149Written as ELX/TEZ/IVA
- A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic FibrosisCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT03912233Written as TEZ
- A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03525548Written as TEZ/IVA
- A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03460990Written as TEZ/IVA
Codes
What other systems call tezacaftor · ClinicalTrials.gg INT000846
- MeSH (NLM) C000625213tezacaftorOne source NLM
- UNII (FDA) 8RW88Y506KTEZACAFTORConfirmed FDA, NLM, Wikidata
- RxNorm 1999382Confirmed FDA, Wikidata
- Wikidata Q27270940tezacaftorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152581TezacaftorOne source FDA
- DrugBank DB11712One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000625213 | tezacaftor | One source NLM |
| UNII (FDA) | 8RW88Y506K | TEZACAFTOR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1999382 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27270940 | tezacaftor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152581 | Tezacaftor | One source FDA |
| DrugBank | DB11712 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.